Video

Pioneers And Visionaries Of Nucleic Acid And Nanoparticle-Based Therapeutics

Source: Cytiva

What does the future of nucleic acid- and nanoparticle-based therapeutics look like? As researchers work to develop new treatments for rare diseases, common cardiometabolic conditions, cancer and more, the possibilities seem endless.

From mRNA and cell therapy to CRISPR gene editing and protein replacement, the new technologies backing the latest vaccines and medicines have the potential to solve complex health problems and tackle diseases once thought untreatable.

While Cytiva works with some of the world’s most innovative and creative therapeutic developers to manufacture their groundbreaking treatments, we’re also learning how to navigate a new and diverse genomic medicine landscape. Hear from a multidisciplinary team that’s applying these lessons to stay ahead of the curve and develop scalable, GMP-ready solutions that will efficiently bring innovative therapeutics — carried by LNPs and other novel delivery technologies — to market and the clinic.

Find out how our expertise, knowledge, and experience are helping researchers and biopharma companies offer new hope for patients with rare diseases, cancer, cardiometabolic conditions, autoimmune conditions, and more.

Episode features: Scott Ripley, Lloyd Jeffs, James Taylor, Jagbir Singh, Angela Zhang.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene